Syndax Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Syndax Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $39.25. The average 1-year stock price forecast is 134.47% higher than the current stock price, while the lowest is $29 (+73.24%) and the highest is $57 (+240.50%).

Price Target: $39.25 (+134.47%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$29	$39.25	$37	$57
Change	+73.24%	+134.47%	+121.03%	+240.50%

Analyst Ratings

The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	11	11	11	11	11
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	13	13	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Corinne Johnson Goldman Sachs	Goldman Sachs	Buy Maintains $34	Buy	Maintains	$34	+103.11%	Jun 4, 2026
Stephen Willey Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $46	Buy	Maintains	$46	+174.79%	Jun 3, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Reiterates $40	Buy	Reiterates	$40	+138.95%	Jun 3, 2026
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Maintains $29	Buy	Maintains	$29	+73.24%	May 21, 2026
David Dai UBS	UBS	Buy Maintains $38 → $37	Buy	Maintains	$38 → $37	+121.03%	May 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

345.52M

from 172.35M

100.47%

from 172.35M

Revenue Next Year

509.75M

from 345.52M

47.53%

from 345.52M

EPS This Year

-1.69

from -3.29

EPS Next Year

-0.47

from -1.69

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	139.71M	-	-	23.68M	172.35M	345.52M
Revenue Growth	9,109.56%	-	-	-	627.84%	100.47%
Gross Profit	139.71M	-118.50M	-163.03M	-218.79M	-93.40M	327.90M
Gross Margin	100.00%	-	-	-923.96%	-54.19%	94.90%
Operating Income	26.22M	-151.76M	-229.95M	-339.67M	-273.08M	-123.04M
Net Income	24.93M	-149.34M	-209.36M	-318.76M	-285.42M	-152.20M
EPS	-	-	-	-	-3.29	-1.69
Free Cash Flow	32.03M	-76.27M	-82.37M	-155.26M	-209.80M	-63.00M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	379.3M
Avg	345.5M
Low	298.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	120.1%
Avg	100.5%
Low	73.2%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.69
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-